Jeffrey S Farrow has sold stock and made no open-market buys since Jun 2020

Jeffrey S. Farrow is a corporate finance and strategy executive who serves as Chief Financial Officer and Chief Strategy Officer of Tarsus Pharmaceuticals, Inc. (TARS), where he is also a reporting insider (“See Remarks”) in recent Form 4 filings.( He has more than two decades of experience leading finance, corporate strategy, and business development functions in the life sciences sector, including at multiple publicly traded biotechnology companies.( At Tarsus, Farrow is the principal financial officer, signing SEC filings and helping guide the company’s evolution into a commercial eye-care organization.(

Before joining Tarsus in 2023, Farrow served as Chief Financial Officer of Global Blood Therapeutics, Inc. (GBT), where he was part of the leadership team that secured regulatory approval and successfully commercialized Oxbryta for sickle cell disease.( Earlier in his career, he held CFO roles at ZS Pharma and Hyperion Therapeutics, contributing to the growth and strategic transactions of both companies.( Public ownership and trading records show Farrow as an insider in Tarsus, Global Blood Therapeutics, and ZS Pharma, reflecting his longstanding involvement with commercial-stage biotech enterprises.( (No specific education details were identified in the available public sources.)

Written by Perplexity from public sources.